Towards the pharmacotherapy of eating disorders

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1659-1678

  Pederson, Kristine J ^a,b   Roerig, James L ^a,c   Mitchell, James E ^a,c  

^a NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

^c UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

Anorexia nervosa; Antidepressants; Antipsychotics; Binge eating disorder; Bulimia nervosa; Eating disorders; Pharmacology; Pharmacotherapy

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYPROHEPTADINE; DOPAMINE 1 RECEPTOR; FLUOXETINE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PIMOZIDE; PLACEBO; RISPERIDONE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; SULPIRIDE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNINDEXED DRUG; VENLAFAXINE;

AGRANULOCYTOSIS; ANOREXIA NERVOSA; BEHAVIOR THERAPY; BINGE EATING DISORDER; BULIMIA; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DIAPHORESIS; DROWSINESS; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESEARCH; DRUG TOLERABILITY; EATING DISORDER; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; NONHUMAN; PERIPHERAL NEUROPATHY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUANTITATIVE ANALYSIS; RELAPSE; REVIEW; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION; XEROSTOMIA;

ANOREXIA NERVOSA; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BULIMIA; EATING DISORDERS; HUMANS; LITHIUM; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; ZINC;

EID: 0142241299     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1659     Document Type: Review

References (158)

1. SULLIVAN PF: Mortality in anorexia nervosa. Am. J. Psychiatry (1995) 152:1073-1074.
2. DSM-IV Eating Disorders. In: Diagnostic and statistical manual of mental disorders (4th edn), Vigersky RA (Ed.), American Psychiatric Association, Washington, DC, USA (1994):539-542.
3. LYRITIS GP, SCHONEAU E, SKARANTAVOS G: Osteopenic syndromes in the adolescent female. Ann. NY Acad. Sci. (2000) 900:403-408.
4. SWENNE I: Heart risk associated with weight loss in anorexia nervosa and eating disorders: electrocardiographic changes during the early phase of refeeding. Acta Pediatr. (2000) 89:447-452.
5. GODART NT, FLAMENT MF, LECRUBIER Y et al.: Anxiety disorders in anorexia nervosa and bulimia nervosa: Comorbidity and chronology of appearance. Eur. Psychiatry (2000) 15:38-45.
6. MITCHELL JE, WONDERLICH S, PETERSON C, CROW S: Psychopharmacology of eating disorders: current knowledge and future directions. In: Eating disorders: new directions for research and practice. Striegel-Moore R, Smolak L (Eds), American Psychological Association Press, New York, USA (2001).
7. STEINHAUSEN HC: The outcome of anorexia nervosa in the 20th century. Am. J. Psychiatry (2003) 160(4):798.
8. KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind placebo-controlled administration of fluoxetine in restricting and purging-type anorexia nervosa. Biol. Psychiatry (2001) 49:644-652.
9. CHANNON S, DeSILVA WP: Psychological correlates of weight gain in patients with anorexia nervosa. J. Psychiatr. Res. (1985) 19:267-271.
10. ECKERT ED, GOLDBERG SC, HALMI KA, CASPER RC, DAVIS JM: Depression in anorexia nervosa. Psychol. Med. (1981) 11:1-8.
11. SLAIMAN S: Restricted diets restrict antidepressant efficacy. Practitioner (1989) 233:974-975.
12. GARLAND EJ, REMICK RA, ZIS AP: Weight gain with antidepressants and lithium. J. Clin. Psychopharmacol. (1988) 8(5):323-330.
13. LACEY JH, CRISP AH: Hunger, food intake and weight: The impact of clomipramine on a refeeding anorexia nervosa population. Postgrad. Med. J. (1980) 56(suppl. 1):79-85.
14. BIEDERMAN J, HERZOG DB, RIVINUS TM et al.: Amitriptyline in the treatment of anorexia nervosa: A double-blind, placebo-controlled study. J. Clin. Psychopharmacol. (1985) 5:10-16.
15. HALMI KA, ECKERT E, LADU TJ, COHEN J: Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch. Gen. Psychiatry (1986) 43:177-181.
16. GOLDBERG SC, HALMI KA, ECKERT ED, CASPER RC, DAVIS JM: Cyproheptadine in anorexia nervosa. Br. J. Psychiatry (1979) 134:67-70.
17. PIGOTT TA: OCD: where the serotonin selectivity story begins. J. Clin. Psychiatry (1996) 57:11-20.
18. ATTIA E, HAIMAN C, WALSH BT, FLATER SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155:548-551.
19. FASSINO S, LEOMBRUNI P, DAGA G et al.: Efficacy of citalopram in anorexia nervosa: a pilot study. Eur. Neuropsychopharmacol. (2002) 12:453-459.
20. RUGGIERO GM, MAURI MC, OMBONI AC et al.: Nutritional management of anorexia patients with and without fluoxetine: 1-year follow-up. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27(3):425-430.
21. SANTONASTASO P, FRIEDERICI S, FAVARO A: Sertraline in the treatment of restricting anorexia nervosa: An open controlled trial. J. Child Adolesc. Psychopharmacol. (2001) 11:143-150.
22. FRANK GK, KAYE WH, MARCUS MD: Sertraline in underweight binge eating/purging-type eating disorders five case reports. Int. J. Eat. Disord. (2001) 29:495-498.
23. CALANDRA C, GULINO V, INSERRA L, GIUFFRIDA A. The use of citalopram in an integrated approach to the treatment of eating disorders: an open trial. Eat. Weight Disord. (1999) 4:207-210.
24. PALLANTI S, QUERCIOLI L, RAMACCIOTTI A: Citalopram in anorexia nervosa. Eat. Weight Disord. (1997) 2:216-221.
25. STROBER M, FREEMAN R, DeANTONIO M, LAMPERT C, DIAMOND J: Does adjunctive fluoxetine influence post-hospital course of anorexia nervosa? A 24-month perspective, longitudinal follow-up and comparison with historical controls. Psychopharmacol. Bull. (1997) 33:425-431.
26. STROBER M, PATAKI C, FREEMAN R, DEANTONIO M: No effect of adjunctive fluoxetine on eating behaviour or weight phobia during the inpatient treatment of anorexia nervosa: a historical case-control study. J. Child Adolesc. Psychopharmacol. (1999) 9:195-201.
27. RUGGIERO GM, LAINI V, MAURI MC: A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog. Neuropsychopharmacol. Biol. Psychiat. (2001) 25:1049-1059.
28. GWIRTSMAN HE, GUZE BH, YAGER J. GAINSLEY B: Fluoxetine treatment of anorexia nervosa: an open clinical trial. J. Clin. Psychiatry (1990) 51:378-382.
29. KAYE WH, WELTZIN TE, HSU LKG, BULIK CM: An open trial of fluoxetine in patients with anorexia nervosa. J. Clin. Psychiatry (1991) 52:464-471.
30. RICCA V, MAMMICCI E, PAOPMMO A et al.: Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: A preliminary study. Eat. Weight Disord. (1999) 4:10-14.
31. ANDERSON I, PARRY-BILLINGS M, NEWSHOLME E et al.: Dieting reduces plasma tryptophan and alters brain serotonin function in women. J. Psychol. Med. (1990) 20:785-791.
32. DELGADO PL, CHARNEY DS, PRICE LH et al.: Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry (1990) 47:411-418.
33. KAYE WH, EBERT MH, RALEIGH M et al.: Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch. Gen. Psychiatry (1984) 41:350-355.
34. KRAUS T, HAACK M, SCHULD A et al.: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry (1999) 156:312-314.
35. PLANANCSKY K: Changes in weight in patients receiving a tranquilizing drug. Psychiatr. Q. (1958) 32:289-303.
36. VANDEREYCKEN W, PIERLOOT R: Pimozide combined with behaviour therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr. Scand. (1982) 66(6):445-450.
37. VANDEREYCKEN W: Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br. J. Psychiatry (1984) 144:288-292.
38. GARDOS G, COLE JO: Overview: public health issues in tardive dyskinesia. Am. J. Psychiatry (1980) 137:776-781.
39. ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156:1686-1696.
40. FISMAN S, STEELE M, SHORT J, BYRNE T, LAVALLEE C: Case study: anorexia nervosa and autistic disorder in an adolescent girl. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:937-940.
41. NEWMAN-TOKER J: Risperidone in anorexia nervosa. J. Am. Acad. Child. Adolesc. Psychiatry (2000) 39:941-942.
42. CARVER AE, MILLER S, HAGMAN J, SIGEL E: The use of risperidone for the treatment of anorexia nervosa. Academy of Eating Disorders Annual Meeting, Boston, USA, April (2002).
43. ALLISON DB, CASEY DE: Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry (2001) 62(Suppl. 7):22-31.
44. HANSEN L: Olanzapine in the treatment of anorexia nervosa. Br. J. Psychiatry (1999) 175:592.
45. JENSEN VS, MEJLHEDE A: Anorexia nervosa: Treatment with olanzapine. Br. J. Psychiatry (2000) 177:187.
46. GASKILL JA, TREAT TA, MCCABE EB, MARCUS MD: Does olanzapine affect the rate of weight gain among inpatients with eating disorders? Eat. Disord. Rev. (2001) 12(6):1-2.
47. LA VIA MC, GRAY L, KAYE WH: Case reports of olanzapine treatment of anorexia nervosa. Int. J. Eat. Disord. (2000) 27:363-366.
48. MEHLER C, WEWETZER C, SCHULZE U, WARNKE A, THEISEN F, DITTMANN RW: Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur. Child. Asolesc. Psychiatry (2001) 10:151-157.
49. POWERS PS, SANTANA CA, BANNON YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord. (2002) 32:146-154.
50. BOACHIE A, GOLDFIELD GS, SPETTIQUE W: Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int. J. Eat. Disord. (2003) 33(1):98-103.
51. GROSS HA, EBERT MH, FADEN VB et al.: A double-blind control trial of lithium carbonate primary anorexia nervosa. J. Clin. Psychopharmacol. (1981) 6:376-381.
52. KATZ RL, KEEN CL, LITT IF et al.: Zinc deficiency in anorexia nervosa. J. Adolesc. Health Care (1987) 8:400-406.
53. LASK B, BRYANT-WAUGH R: Zinc deficiency and childhood-onset anorexia nervosa. J. Clin. Psychiatry (1993) 54:63-66.
54. BIRMINGHAM CL, GOLDNER EM, BAKAN R. Controlled trial of zinc supplementation in anorexia nervosa. Int. J. Eat. Disord. (1994) 15:251-255.
55. SU JC, BIRMINGHAM CL: Zinc supplementation in the treatment of anorexia nervosa. Eat. Weight Disord. (2002) 7:20-22.
56. GROSS H, EBERT MH, FADEN VB et al.: A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharmacol. (1983) 3:165-171.
57. MARRAZZI MA, BACON JP, KINZIE J, LUBY ED: Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int. Clin. Psychopharmacol. (1995) 10:163-172.
58. CASPER RC, SCHLEMMER RF, JAVAID JI: A placebo-controlled crossover study of oral clonidine in acute anorexia nervosa. Psychiatry Res. (1987) 20:249-260.
59. HILL K, BUCUVALAS J, MCCLAIN C: Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J. Child. Adolesc. Psychopharmacol. (2000) 10:3-8.
60. DOMSTAD PA, SHIH WJ, HUMPHRIES L, DELAND FH, DIGENIS GA: Radionuclide gastric emptying studies in patients with anorexia nervosa. J. Nucl. Medicine (1987) 28:816-819.
61. STACHER G, BERGMANN H., WIESNAGROTZKI S et al.: Intravenous cisapride accelerated delayed gastric emptying and increases antral contraction amplitude with primary anorexia nervosa. Gastroenterology (1987) 92:1000-1006.
62. STACHER G, KISS A, WIESNAGROTZKI S, BERGMANN H, HOBART J, SCHNEIDER C: Oesophageal and gastric motility disorders in patients categorized as having primary anorexia nervosa. Gut (1986) 27:1120-1126.
63. CRAIGEN D, KENNEDY SH, GARFINKEL PE, JEEJEEBHOY K: Drugs that facilitate gastric emptying. In: The role of drug treatments for eating disorders, Garfinkel PE, Garner DM (Eds), Brunnel/Mazel, New York, USA, (1987):161-176.
64. MOLDOFSKY H, JEUNIEWIC N, GARFINKEL PJ: Primary report of metoclopramide in anorexia nervosa. In: Anorexia nervosa. Vigersky RA (Ed.) Raven Press, New York, USA (1977):373-376.
65. STACHER G, ABATZI-WENZEL TA, WIESNAGROTZKI S, BERGMANN H, SCHNEIDER C, GAUPMANN G: Gastric emptying, body weight and symptoms in primary anorexia nervosa. Long-term effects of cisapride. Br. J. Psychiatry (1993) 162:398-402.
66. SZMUKLER GI, YOUNG GP, MILLER G, LICHTENSTEIN M, BINNS DS: A controlled trial of cisapride in anorexia nervosa. Int. J. Eat. Disord. (1995) 17:347-357.
67. AGRAS WS: The consequences and costs of the eating disorders. Psychiatr. Clin. North Am. (2001) 24(2):371-379.
68. KENNEDY SH, PIRAN N, WARSH JJ et al.: A trial of isocarboxazid in the treatment of bulimia nervosa. J. Psychopharmacol. (1988) 8:391-396.
69. WALSH BT, GLADIS M, ROOSE SP et al.: Phenelzine versus placebo in 50 patients with bulimia. Arch. Gen. Psychiatry (1988) 45:471-475.
70. KENNEDY SH, GOLDBLOOM DS, RALEVSKI E: Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. J. Clin. Psychopharmacol. (1993) 13:415-422.
71. ROTHSCHILD R, QUITKIN HM, QUITKIN FM et al.: A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int. J. Eat. Disord. (1994) 15:1-9.
72. WALSH BT, STEWART JW, ROOSE SP et al.: Treatment of bulimia with phenelzine: A double-blind placebo controlled study. Arch. Gen. Psychiatry (1984) 41:1105-1109.
73. WALSH BT, STEWART JW, ROOSE SP et al.: A double-blind trial of phenelzine in bulimia. J. Psychiat. Res. (1985) 19:485-489.
74. POPE HG Jr, HUDSON JI, JONAS JM, YURGELUN-TODD D: Bulimia treated with imipramine: a placebo-controlled, double-blind study. Am. J. Psychiatry (1983) 140:554-558.
75. MITCHELL JE, GROAT R: A placebo-controlled double-blind trial of amitriptyline in bulimia. J. Clin. Psychopharmacol. (1984) 4:186-193.
76. HUGHES PL, WELLS LA, CUNNINGHAM CJ, ILSTRUP DM: Treating bulimia with desipramine. Arch. Gen. Psychiatry (1986) 43:182-186.
77. AGRAS WS, DORIAN B, KIRKLEY BG, ARNOW B, BACHMAN J: Imipramine in the treatment of bulimia: A double blind controlled study. Int. J. Eat. Disord. (1987) 6:29-38.
78. BARLOW J, BLOUIN J, BLOUIN A, PEREZ E: Treatment of bulimia with desipramine: a double-blind crossover study. Can. J. Psychiatry (1998) 33:129-133.
79. BLOUIN AG, BLOUIN JH, PEREZ EL, BUSHNIK T, ZURO C, MULDER E: Treatment of bulimia with fenfluramine and desipramine. J. Clin. Psychopharmacol. (1988) 8:261-269.
80. ALGER SA, SCHWALBERG MD, BIGAOUTTE JM et al.: Effects of a tricyclic antidepressant and opiate antagonists on binge-eating behaviour in normal weight bulimic and obese binge-eating subjects. J. Clin. Nutr. (1991) 53:865-871.
81. HORNE RL, FERGUSON JM, POPE HG et al.: Treatment of bulimia with bupropion: A multi-centre controlled trial. J. Clin. Psychiatry (1988) 49:262-266.
82. FICHTER MM, KRUGER R, RIEF W et al.: Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating on eating-specific psychopathology. J. Clin. Psychopharmacol. (1996) 16:9-18.
83. FLUOXETINE BULIMIA NERVOSA COLLABORATIVE STUDY GROUP: Fluoxetine in the treatment of bulimia nervosa. Arch. Gen. Psychiatry (1992) 49:139-147.
84. GOLSTEIN DJ, WILSON MG, THOMPSON VL, POTUIN JH, RAMPEY AH: Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br. J. Psychiatry (1995) 166:660-666.
85. ROMANO S: Fluoxetine maintenance therapy for bulimia nervosa. Paper presented at the annual meeting of the Eating Disorders Research Society, San Diego, CA (1999, November).
86. GOLSTEIN DJ, WILSON MG, ASCROFT RC et al.: Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int. J. Eat. Disord. (1999) 25(1):19-27.
87. ROMANO SJ, HALMI KA, KOKE SC, LEE JS: A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa, after successful actue fluoxetine treatment. Am. J. Psychiatry (2002) 159:96-102.
88. AGRAS WS: Pharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomes. (1997) 33:433-436.
89. NAKASH-EISIKOVITS O, DIERBERGER A, WESTEN D: A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarizing the range of outcomes in controlled clinical trials. Harvard Rev. Psychiatry (2002) 10:193-211.
90. AGRAS WS, SCHNEIDER JA, ARNOW B et al.: Cognitive-behavioral and response prevention treatments for bulimia nervosa. J. Consult. Clin. Psychol. (1989) 57:215-221.
91. FREEMAN CP, BARRY F, DUNKELD-TRUNBULL J et al.: Controlled trial of psychotherapy for bulimia nervosa. Br. Med. J. (1988) 296:521-525.
92. GARNER DM, ROCKERT W, DAVIS R, GARNER MV et al.: A comparison of cognitive-behavioral and supportive-expressive therapy for bulimia nervosa. Am. J. Psychiatry (1993) 150:37-46.
93. KIRKLEY BG, SCHNEIDER JA, AGRAS WS et al.: Comparison of two group treatments for bulimia. J. Consult. Clin. Psychol. (1985) 53:43-48.
94. LAESSLE RG, ZOETTLE C, PIRKE KM: Meta-analysis of treatment studies for bulimia. Int. J. Eat. Disord. (1987) 6:647-654.
95. LEE NF, RUSH AJ: Cognitive-behavioral group therapy for bulimia. Int. J. Eat. Disord. (1986) 5:599-615.
96. LEITENBERG H, ROSEN J, GROSS J et al.: Exposure plus response-prevention treatment of bulimia nervosa. J. Consult. Clin. Psychol. (1988) 56:535-541.
97. ORDMAN AM, KIRSCHENBAUM DS: Cognitive-behavioral therapy for bulimia: an initial outcome study. J. Consult. Clin. Psychol. (1985) 53:305-313.
98. TREASURE J, SCHMIDT U, TROOP N et al.: Sequential treatment for bulimia nervosa incorporating self-care manual. Br. J. Psychiatry (1995) 167:1-5.
99. WILSON GT, ELDREDGE KL, SMITH D: Cognitive behavioral treatment with and without response prevention for bulimia. Behav. Res. Ther. (1991) 29:575-583.
100. WILSON GT, ROSSITER E, KLEIFIELD EI et al.: Cognitive behavioral treatment of bulimia nervosa: a controlled evaluation. Behav. Res. Ther. (1986) 24:277-288.
101. AGRAS WS, WALSH T, WILSON G: A multisite comparison of cognitive behaviour therapy (CBT) and interpersonal therapy (IPT) in the treatment of bulimia nervosa. 4th International Conference on Eating Disorders, London, UK, April 20 - 22, (1999):61.
102. FAIRBURN CG, JONES R, PEVELER RC et al.: Psychotherapy and bulimia nervosa: longer-term effects of interpersonal psychotherapy, behaviour therapy, and cognitive behavioral therapy. Arch. Gen. Psychiatry (1993) 50:419-428.
103. FAIRBURN CG, JONES R, PEVELER RC: Three psychological treatments for bulimia nervosa. Arch. Gen. Psychiatry (1991) 48:453-469.
104. FAIRBURN CG, KIRK J, O'CONNER M et al.: A comparison of two psychological treatments for bulimia nervosa. Behav. Res. Ther. (1986) 24:629.
105. FAIRBURN CG, NORMAN PA, WALSH SL et al.: A prospective study of outcome in bulimia nervosa and the long-term effects of three psychological treatments. Arch. Gen. Psychiatry (1995) 52:304-312.
106. LEITENBERG H, ROSEN JC, WOLF J et al.: Comparison of cognitive behaviour therapy and desipramine in the treatment of bulimia nervosa. Behav. Res. Ther. (1994) 32:37-45.
107. GOLDBLOOM DS, OLMSTED M, DAVIS R et al.: A randomised controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav. Res. Ther. (1997) 35:803-811.
108. MITCHELL JE, PYLE, RI, ECKERT ED et al.: A comparison study of antidepressants and structured intensive group psychotherapy in the treatment for bulimia nervosa. Arch. Gen. Psychiatry (1990) 47:149-157.
109. AGRAS WS, ROSSITER EM, ARNOW B et al.: Pharmacological and cognitive behavioral treatment for bulimia nervosa a controlled comparison. Am. J. Psychiatry (1992) 149:82-87.
110. WALSH BT, WILSON GT, LOEB KL et al.: Medication and psychotherapy in the treatment of bulimia nervosa. Am. J. Psychiatry (1997) 154:523-531.
111. MITCHELL JE, PETERSON CB, MYERS T, WONDERLICH SA: Combining pharmacotherapy and psychotherapy in the treatment of patients with eating disorders. In: The Psychiatric Clinics of North America. Anderson AE (Ed.), WB Saunders Co., Philadelphia, USA (2001):315-323.
112. WALSH BT, AGRAS WS, DEVLIN MJ et al.: Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am. J. Psychiatry (2000) 157(8):1332-1334.
113. HAY PJ, BACALTCHUK J: Psychotherapy for bulimia nervosa and binging. In: The Cochrane Library, 3:(2003), Cochrane review.
114. BACALTCHUK J, HAY P, TREFIGLIO R: Antidepressants versus psychological treatment and their combination for bulimia nervosa. In: The Cochrane Library 3:(2003), Cochrane review.
115. HARTMAN BK, FARIS PL, KIM SW et al. Treatment of bulimia nervosa with ondansetron. Arch. Gen. Psychiatry (1997) 54(10):969-970.
116. FARIS PL, KIM SW, MELLER WH, GOODALE RL et al.: Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa a randomised, double-blind trial. The Lancet (2000) 355:792-797.
117. BARBEE JG: Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int. J. Eat. Disord. (2003) 33(4):468-472.
118. HOOPES, REIMHERR et al.: Topiramate in bulimia nervosa. APA (2002).
119. FAHY TA, EISLER I, RUSSELL FM: A placebo-controlled trial of d-Fenfluramine in bulimia nervosa. Br. J. Psychiatry (1993) 162:597-603.
120. RUSSELL GFM, CHECKLEY SA, FELDMAN J, EISLER I: A controlled trial of d-Fenfluramine in bulimia nervosa. Clin. Neuropharmacol (1988) 11:S146-S159.
121. HSU LK, CLEMENT L, SANTHOUSE R, JU ES: Treatment of bulimia nervosa with lithium carbonate: a controlled study. J. Nervous Mental Disord. (1991) 179:351-355.
122. WERMUTH BM, DAVIS KL, HOLLISTER LE: Phenytoin treatment of the binge eating syndrome. Am. J. Psychiatry (1977) 134:1249-1253.
123. INGOIN-APFELBAUM L, APFELBAUM M: Naltrexone and bulimic symptoms. Lancet (1987) 2:1087-1088.
124. MITCHELL JE, CHRISTENSON G, JENNINGS J et al.: A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in patients with normal weight bulimia. J. Clin. Psychopharmacol. (1989) 9:94-97.
125. WALSH BT, HADIGAN CM, DEVLIN MJ et al.: Long-term outcome of antidepressant treatment for bulimia nervosa. Am. J. Psychiatry (1991) 148:1206-1212.
126. SABINE EJ, YONACE A, FARINGTON AJ et al.: Bulimia nervosa: a placebo-controlled double-blind therapeutic trial of mianserin. Br. J. Clin. Pharmacol. (1983) 15(2):195S-202S.
127. POPE HG Jr, KECK PE Jr, MCELROY SL et al.: A placebo-controlled study of trazodone in bulimia nervosa. J. Clin. Psychopharmacol. (1989) 9:254-259.
128. CARRUBA MD, CUZZOLARO M, RIVA L et al.: Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int. Clin. Psychopharmacol. (2001) 16:27-32.
129. JACOBI C, DAHME B, DITTMANN RW: Cognitive-behavioral, fluoxetine and combined treatment for bulimia nervosa: short-term and long-term results. Eur. Eat. Disord. Rev. (2002) 10:179-198.
130. FICHTER MM, LEIBL K, RIEF W et al.: Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry (1991) 24:1-7.
131. BEUMONT PJV, RUSSELL JD, TOUYZ SW et al.: Intensive nutritional counseling in bulimia nervosa: a role for supplementation with fluoxetine? Aust. NZ J. Psychiatry (1997) 31:514-524.
132. MITCHELL JE, HALMI K, WILSON GT et al.: A randomised secondary treatment study of women with bulimia nervosa who fail to respond to CBT. Int. J. Eat. Disord. (2002) 32(3):271-281.
133. WILLIAMSON DA, MARTIN CK: Binge eating disorder: a review of the literature after publication of DSM-IV. Eat. Weight Disord. (1999) 4:103-114.
134. SMITH DE, MARCUS MD, LEWIS CE et al.: Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults. Ann. Behav. Med. (1998) 20:227-232.
135. DEVLIN M: Psychotherapy and medication for binge eating disorder, Abstract Plenary Session, International Conference on Eating Disorders, Boston, USA, April 25 - 28 (2002).
136. WADDEN TA, SARWER DB, WOMBLE LG et al.: Psychosocial aspects of obesity and obesity surgery. Surg. Clin. North Am. (2001) 81:1004-1024.
137. MCCANN UD, AGRAS WS: Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am. J. Psychiatry (1990) 147:1509-1513.
138. ALGER SA, MALONE M, CERULLI J, FEIN S, HOWARD L: Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. Obes. Res. (1999) 7:469-476.
139. LAEDERACH-HOFMAN K, GRAF C, HORBER F et al.: Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomised, placebo-controlled double-blind study. Int. J. Eat. Disord. (1999) 26:231-244.
140. MARCUS MD, WING RR, EWING L, KERM E, MCDERMOTT M, GOODING W: A double-blind, placebo-controlled trial of fluoxetine plus behaviour modification in the treatment of obese binge-eaters and non-binge-eaters. Am. J. Psychiatry (1990) 147:876-881.
141. DE ZWAAN M, NUTZINGER DO, SCHÖNBECK G: Binge eating in overweight females. Compr. Psychiatry (1992) 33:256-261.
142. HUDSON JI, MCELROY SL, RAYMOND NC et al.: Fluvoxamine in the treatment of binge-eating disorder. Am. J. Psychiatry (1998) 155:1756-1762.
143. MCELROY SL, ARNOLD LM, SHAPIRA NA et al.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomised, placebo-controlled trial. Am. J. Psychiatry (2003) 160:255-261.
144. RICCA V, MANNUCCI E, MEZZANI B et al.: Fluoxetine and fluvoxamine combined with individual cognitive-behavior therapy in binge eating disorder: a one-year follow-up study. Psychother. Psychosom. (2001) 70:298-306.
145. GRILO CM, MASHEB RM, HENINGER G, WILSON GT: Psychotherapy and medication for binge eating disorder, International Conference on Eating Disorders, Boston, USA, April 25 - 28 (2002) (Abstract 095).
146. ARNOLD LM, McELROY SL, HUDSON JI, WELGE JA, BENNETT AJ, KECK PE: A placebo-controlled, randomised trial of fluoxetine in the treatment of binge-eating disorder. J. Clin. Psychiatry (2002) 63(11):1028-1033.
147. STUNKARD A, BERKOWITZ R, TANRIKUT C, REISS E, YOUNG L: D-Fenfluramine treatment of binge eating disorder. Am. J. Psychiatry (1996) 153:1455-1459.
148. YANOVSKI SZ,YANOVSKI MD: Obesity. N. Engl. J. Med. (2002) 346:591-602.
149. RYAN DH, KAISER P, BRAY GA: Sibutramine: a novel new agent for obesity treatment. Obes. Res. (1995) 3(Suppl. 4):553S-559S.
150. BRAY GA, RYAN DH, GORDON D, HEIDINGSFELDER S, CERISE F, WILSON K: A double-blind randomised placebo-controlled trial of sibutramine. Obes. Res. (1996) 3:263-270.
151. JAMES WPT, ASTRUP A, FINER N et al.: Effects of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Lancet (2000) 356:219-2125.
152. MALHOTRA S, KING KH, WELGE JA, BRUSMAN-LOVINS L, McELROY SL: Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J. Clin. Psychiatry (2002) 63:802-806.
153. APPOLINARIO JC, GODOY-MATTOS A, FONTENELLE LF et al.: An open trial of sibutramine in obese patients with binge eating disorder. J. Clin. Psychiatry (2002) 63:28-30.
154. LANGTRY HD, GILLIS JC, DAVIS R: Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs (1997) 54:752-773.
155. APPOLINARIO JC, BACALTCHUK J, SICHIERI et al.: A randomised, double-blind, placebo-controlled study of Sibutramine in the treatment of binge eating disorder. Arch. Gen. Psychiatry (2003) (In Press).
156. STANLEY BG, HA LH, SPEARS LC et al.: Lateral hypothalamic injections of glutamate, kainic acid, D, L-alpha-amino-3-hydrozy-5-methyl-isoxazole propionic acid or N-methyl-D-aspartic acid rapidly elicits intense transient eating in rats. Brain Res. (1993) 613:88-95.
157. SMITH U, AXELSEN M, HELLEBO-JOHANSON E et al.: Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity. Obes. Res. (2000) 8(Suppl. 1):105 (Abstract).
158. APPOLINARIO JC, COUTINHO W, FONTENELLE LF.: Topiramate for binge eating disorder. Am. J. Psychiatry (2001) 158(6):967-968.